Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 20 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact20 DOIs

Add abstracts to 14 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact14 DOIs

Deposit reference lists for 12 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact12 DOIs

DOIs for this ISSN

Showing the top 5 of 153 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	A historical perspective on HLA (10.1093/immadv/ltad014)	ORCID	28.65	13
2	Special Review: The future of Immunotherapy (10.1093/immadv/ltaa005)	ORCID	23.86	8
3	Introducing <i>Immunotherapy Advances</i> (10.1093/immadv/ltaa009)	Abstract ORCID	23.86	2
4	Immunotherapy advances: One year on (10.1093/immadv/ltac001)	Abstract ORCID	23.86	2
5	Correction (10.1093/immadv/ltac018)	Abstract References ORCID	22.58	1
6	Beyond Ipilimumab: a review of immunotherapeutic approaches… (10.1093/immadv/ltaa010)	ORCID	17.47	4
7	Harnessing immunometabolism for cardiovascular health and ca… (10.1093/immadv/ltab021)	Abstract	17.47	4
8	Predicting clinical response to costimulation blockade in au… (10.1093/immadv/ltaa003)	ORCID	15.05	3
9	High level of anti-drug antibodies is associated with shorte… (10.1093/immadv/ltaf019)	ORCID	7.53	1
10	Head-to-head comparison of nuclear imaging approaches to qua… (10.1093/immadv/ltaf027)	References	7.53	1
11	Protective low-avidity anti-tumour CD8+ T cells are selectiv… (10.1093/immadv/ltaa001)		0.00	9
12	The MARVEL trial: a phase 2b randomised placebo-controlled t… (10.1093/immadv/ltaa002)		0.00	14
13	DNAM1 and TIGIT balance the T cell response, with low T cell… (10.1093/immadv/ltaa004)		0.00	5
14	CAR-T cells leave the comfort zone: current and future appli… (10.1093/immadv/ltaa006)		0.00	11
15	Recent advances in immunotherapies against infectious diseas… (10.1093/immadv/ltaa007)		0.00	54
16	Vitamin D3 replacement enhances antigen-specific immunity in… (10.1093/immadv/ltaa008)		0.00	23
17	Regulating innovation in the early development of cell thera… (10.1093/immadv/ltaa011)		0.00	3
18	Upcoming immunotherapeutic combinations for B-cell lymphoma (10.1093/immadv/ltab001)		0.00	4
19	Integrin-directed antibody-based immunotherapy: focus on VLA… (10.1093/immadv/ltab002)		0.00	10
20	CSF1R defines the mononuclear phagocyte system lineage in hu… (10.1093/immadv/ltab003)		0.00	16
21	An overview of CAR T-cell clinical trial activity to 2021 (10.1093/immadv/ltab004)		0.00	21
22	Immuno-antibiotics: targeting microbial metabolic pathways s… (10.1093/immadv/ltab005)		0.00	4
23	MicroRNAs: immune modulators in cancer immunotherapy (10.1093/immadv/ltab006)		0.00	36
24	Adaptive immunity and vaccination – iron in the spotlight (10.1093/immadv/ltab007)		0.00	16
25	Behind the scenes with basophils: an emerging therapeutic ta… (10.1093/immadv/ltab008)		0.00	24
26	Advancement of antigen-specific immunotherapy: knowledge tra… (10.1093/immadv/ltab009)		0.00	22
27	A glutamine ‘tug-of-war’: targets to manipulate glutamine me… (10.1093/immadv/ltab010)		0.00	26
28	Type 2 immunity is maintained during cancer-associated adipo… (10.1093/immadv/ltab011)		0.00	15
29	α2-3 Sialic acid binding and uptake by human monocyte-derive… (10.1093/immadv/ltab012)		0.00	19
30	Targeting immunometabolism to treat COVID-19 (10.1093/immadv/ltab013)		0.00	41
31	Association between incidental statin use and skeletal myopa… (10.1093/immadv/ltab014)		0.00	22
32	Peripheral T cell lymphopenia in COVID-19: potential mechani… (10.1093/immadv/ltab015)		0.00	43
33	Enhancing co-stimulation of CAR T cells to improve treatment… (10.1093/immadv/ltab016)		0.00	21
34	Oral tolerance as antigen-specific immunotherapy (10.1093/immadv/ltab017)		0.00	29
35	A summary of current NKG2D-based CAR clinical trials (10.1093/immadv/ltab018)		0.00	71
36	The clinical correlates of vaccine-induced immune thrombotic… (10.1093/immadv/ltab019)		0.00	7
37	Potential human immunotherapeutics for plague (10.1093/immadv/ltab020)		0.00	5
38	A phase 1b open-label dose-finding study of ustekinumab in y… (10.1093/immadv/ltab022)		0.00	20
39	Editor’s Note: Relates to: ‘Immuno-antibiotics: targeting mi… (10.1093/immadv/ltab023)	Abstract References ORCID	0.00	0
40	100 years post-insulin: immunotherapy as the next frontier i… (10.1093/immadv/ltab024)		0.00	9
41	Seven mysteries of LAG-3: a multi-faceted immune receptor of… (10.1093/immadv/ltab025)		0.00	58
42	HBV-HCC treatment with mRNA electroporated HBV-TCR T cells (10.1093/immadv/ltab026)		0.00	14
43	Human neutralizing antibodies for SARS-CoV-2 prevention and… (10.1093/immadv/ltab027)		0.00	12
44	Safety of the use of gold nanoparticles conjugated with proi… (10.1093/immadv/ltac002)		0.00	54
45	Engineering CAR-NK cells: how to tune innate killer cells fo… (10.1093/immadv/ltac003)		0.00	22
46	Peanut oral immunotherapy: current trends in clinical trials (10.1093/immadv/ltac004)		0.00	15
47	Combination of genetically engineered T cells and immune che… (10.1093/immadv/ltac005)		0.00	31
48	New and emerging concepts and therapies for the treatment of… (10.1093/immadv/ltac006)		0.00	16
49	Reduced cytotoxicity by mutation of lysine 590 of <i>Pseudom… (10.1093/immadv/ltac007)		0.00	0
50	Balancing the good and the bad: controlling immune-related a… (10.1093/immadv/ltac008)		0.00	9